Treatment of PED With AMT & Autologous Serum

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Patients with persistent corneal epithelial defects who have not responded to conventional therapy will be randomized to treatment with either amniotic membrane transplantation or autologous serum 20%. Outcome measures will be (1) presence or absence of complete re-epithelialization within 28 days and (2) retention of intact epithelium for at least 90 days.

See also
Status	Clinical Trial	Phase
Completed	`NCT01075347` - Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries	Phase 1
Completed	`NCT06213727` - ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects in a Phase Ⅱ Clinical Trial	Phase 2
Active, not recruiting	`NCT01168375` - The Role of Umbilical Cord Serum Therapy on Improvement of Corneal Epithelial Defect Following Diabetic Vitrectomy	Phase 1

NCT number	NCT00238862
Study type	Interventional
Source	King Khaled Eye Specialist Hospital
Contact
Status	Completed
Phase	N/A
Start date	October 2005
Completion date	September 2006

Treatment of PED With AMT and Autologous Serum

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms